PharmaCyte Biotech Inc (PMCB) Stock Analysis

AI analysis of PharmaCyte Biotech Inc (PMCB)

Buy

PharmaCyte Biotech Inc (PMCB) appears to be a good buy right now due to its recent price performance and favorable technical indicators. The current price is $0.36, which is near the 52-week low of $0.30, indicating potential for upside as it has a 52-week high of $1.51. The stock has shown a 5-day change of +19.17%, suggesting a positive short-term momentum. Additionally, the forward P/E ratio is 7.02, indicating that the stock may be undervalued relative to its future earnings potential. However, a significant risk is the negative net income reported for the last quarter at -$4,873,411, which reflects ongoing financial challenges. Overall, the combination of a low entry price, potential for recovery, and positive short-term trends supports a buy recommendation.

Valuation Metrics

The current forward P/E ratio for PharmaCyte Biotech Inc (PMCB) is 7.02, compared to its 5-year average forward P/E of -3.89.

Forward P/E

Overvalued

5Y Average P/E

-3.89

Current P/E

7.02

Overvalued

1.63

Undervalued

-9.41

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Alphio AI Price Scenarios for PMCB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PMCB

$0.97

Scenario price

B

Base

Base · 50%PMCB

$0.95

Scenario price

B

Bear

Bear · 25%PMCB

$0.86

Scenario price

PMCB FAQ — answered by Alphio AI

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

PharmaCyte Biotech Inc (PMCB) appears to be a good buy right now due to its recent price performance and favorable technical indicators. The current price is $0.36, which is near the 52-week low of $0.30, indicating potential for upside as it has a 52-week high of $1.51. The stock has shown a 5-day change of +19.17%, suggesting a positive short-term momentum. Additionally, the forward P/E ratio is 7.02, indicating that the stock may be undervalued relative to its future earnings potential. However, a significant risk is the negative net income reported for the last quarter at -$4,873,411, which reflects ongoing financial challenges. Overall, the combination of a low entry price, potential for recovery, and positive short-term trends supports a buy recommendation.